|
Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime
Time?
Apr 16, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Apr 16, 2026 What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Apr 16, 2026 Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Apr 16, 2026 Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation? Apr 16, 2026 Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603 Apr 16, 2026 Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Apr 16, 2026 Circulating Tumor DNA for Minimal Residual Disease in Colon Cancer: Ready for Prime Time? Apr 16, 2026 Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial Apr 16, 2026 Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status Apr 16, 2026 What Money Cannot Buy: Addressing the Socioeconomic Status Ceiling Effect for Black Patients Across Cancer Types Apr 16, 2026 Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium Apr 16, 2026 Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters Apr 16, 2026 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability–High Gastric Cancer: Solid Evidence or Premature Extrapolation? Apr 16, 2026 |
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond Journal of Clinical Oncology, Volume 44, Issue 18, Page 1720-1729, June 2026. <br/> 2026-06-20T07:00:00Z Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial Journal of Clinical Oncology, Volume 44, Issue 18, Page 1676-1686, June 2026. <br/> 2026-06-20T07:00:00Z Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial Journal of Clinical Oncology, Volume 44, Issue 18, Page 1697-1708, June 2026. <br/> 2026-06-20T07:00:00Z Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial Journal of Clinical Oncology, Volume 44, Issue 18, Page 1687-1696, June 2026. <br/> 2026-06-20T07:00:00Z Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy Journal of Clinical Oncology, Volume 44, Issue 18, Page 1730-1744, June 2026. <br/> 2026-06-20T07:00:00Z Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE) Journal of Clinical Oncology, Volume 44, Issue 18, Page 1709-1719, June 2026. <br/> 2026-06-20T07:00:00Z Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study Journal of Clinical Oncology, Volume 44, Issue 18, Page 1670-1675, June 2026. <br/> 2026-06-20T07:00:00Z Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1 Journal of Clinical Oncology, Volume 44, Issue 18, Page e101-e112, June 2026. <br/> 2026-06-20T07:00:00Z Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1 Journal of Clinical Oncology, Volume 44, Issue 18, Page e89-e100, June 2026. <br/> 2026-06-20T07:00:00Z Cracks in the Estrogen Carcinogenesis of Breast Cancer Journal of Clinical Oncology, Volume 44, Issue 18, Page 1660-1664, June 2026. <br/> 2026-06-20T07:00:00Z Menopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibition Journal of Clinical Oncology, Volume 44, Issue 18, Page 1665-1669, June 2026. <br/> 2026-06-20T07:00:00Z Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS Journal of Clinical Oncology, Volume 44, Issue 18, Page 1747-1748, June 2026. <br/> 2026-06-20T07:00:00Z Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno Journal of Clinical Oncology, Volume 44, Issue 18, Page 1745-1746, June 2026. <br/> 2026-06-20T07:00:00Z Reply to: Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno Journal of Clinical Oncology, Volume 44, Issue 18, Page 1746-1747, June 2026. <br/> 2026-06-20T07:00:00Z Reply to: Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS Journal of Clinical Oncology, Volume 44, Issue 18, Page 1748-1749, June 2026. <br/> 2026-06-20T07:00:00Z Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma Journal of Clinical Oncology, Volume 44, Issue 18, Page 1657-1659, June 2026. <br/> 2026-06-20T07:00:00Z |
When Health Costs No Longer Count — Air Pollution and EPA Rulemaking
The EPA has decided to stop considering the monetary value of public health benefits in federal rulemaking related to air pollution. This decision could have profound health consequences. 2026-06-20
Prehospital Whole Blood in Traumatic Hemorrhage — A Randomized Controlled Trial Among patients with traumatic hemorrhage, prehospital whole-blood transfusion was not superior to standard transfusion with red-cell and plasma components in reducing the risk of death or massive transfusion. 2026-06-18
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial Among patients with moderate or severe PTS, the addition of endovascular therapy to standard care resulted in less severe PTS and better quality of life at 6 months than standard care alone but with a higher risk of bleeding. 2026-06-18
Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood. 2026-06-18
Management of Differentiated Thyroid Cancer This review of the evolving management of differentiated thyroid cancer highlights overdiagnosis of low-risk disease, dynamic risk stratification, active surveillance or ablation, targeted therapies, and active patient involvement. 2026-06-18
Case 17-2026: A 74-Year-Old Man with Pancytopenia A 74-year-old man with a recent orthotopic heart transplantation was admitted to the hospital because of persistent pancytopenia that resulted in serial transfusions of packed red cells. A diagnosis was made. 2026-06-18
Stenting for Post-Thrombotic Syndrome — A Step Forward Post-thrombotic syndrome is the most common chronic complication of deep-vein thrombosis (DVT), affecting 20 to 50% of patients with DVT and causing debilitating symptoms involving the limbs — including pain, swelling, skin changes, and venous ulcers — that substantially reduce quality of life and impose considerable socioeconomic burden.1 ... 2026-06-18
Prehospital Whole Blood for Traumatic Hemorrhage — Consistent Evidence from Two Randomized Trials Hemorrhagic shock remains the leading cause of preventable death after injury.1 Over the past two decades, early administration of blood products has transformed care for patients with bleeding. The Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial2 established that among patients with severe trauma and... 2026-06-18
Stemness as the Engine of Checkpoint Durability The clinical benefits of checkpoint inhibitors in the treatment of cancer often wane. A preclinical study points to a potential strategy for a more durable effect. 2026-06-18
Immunosuppression-Associated Peripheral T-Cell Lymphoma A 66-year-old man with a history of Crohn’s disease treated with long-term adalimumab presented with fever and swelling of both knees. Analysis of a biopsy sample of the left knee synovium showed an atypical T-cell infiltrate. 2026-06-18
Intravenous Artesunate in Artemisinin-Resistant Severe Malaria in Uganda In an African study of severe malaria in children with partially artemisinin-resistant parasites with PfK13 mutations, artesunate did not lead to worse outcomes, which suggests that parenteral artesunate may still be used. 2026-06-18
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema In a phase 3, randomized trial of lonvo-z, an in vivo gene editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. 2026-06-13
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. 2026-06-13
Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease The authors report the results of interim analyses of two phase 3 studies of exa-cel, a gene-edited cellular therapy, in children with transfusion-dependent β-thalassemia or sickle cell disease. 2026-06-11
Antidotes for Anticoagulation Reversal The authors review current strategies for anticoagulation reversal in major bleeding events or urgent surgery as well as specific antidotes, limits of available evidence, thrombotic risks, unmet therapeutic needs, and ongoing research. 2026-06-11
Osteosarcoma An 11-year-old girl presented with a 1-month history of right thigh pain that worsened at night. Radiographs of the knee revealed a metaphyseal osteoblastic lesion with a sunburst appearance. 2026-06-11
Prescription without Precision — Dangers of Dosing on the Basis of Race as Biology Despite recognition that racial and ethnic categories are poor proxies for genetic diversity, race is still used to guide pharmaceutical use, posing risks of ineffectively low or dangerously high dosing. 2026-06-11
Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days. 2026-06-10
TRACTION for Greater Surgical Use of Tranexamic Acid Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid just before the surgery. This failing is due not to a lack of high-quality scientific evidence on the overall safety, efficacy,... 2026-06-10
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia In a phase 1–2 trial involving patients with acute myeloid leukemia, the use of oral decitabine–cedazuridine with venetoclax induced a complete response in 47% of patients, with expected myelosuppressive effects. 2026-06-04
|
|
|
| |||
|
[Editorial] The promise and perils of AI in oncology
Technological innovations in health care—including artificial intelligence (AI)—have rapidly transformed core components of oncology care. With public health-care systems under substantial financial strain, advancing digital technology has become a game-changing tool in modern oncology workflows. Such technology offers the potential for more precise, efficient, and cost-effective interventions and could help to revolutionise clinical trials, cancer diagnosis, treatment, and health outcomes; reduce waiting times; and ease pressure on health-care services. Mon, 01 Jun 2026 00:00:00 -0700
[Comment] Reshaping breast cancer radiotherapy after FAST-Forward Breast radiotherapy is an integral component of breast cancer care to reduce locoregional recurrence.1 Historically, radiotherapy was delivered daily in 25–30 fractions over 5–6 weeks. Radiobiological and technological advances have enabled hypofractionation: shorter courses with larger doses per fraction achieve similar tumour control while reducing late tissue effects through reduced total dose.2 This approach was established in the first generation breast hypofractionation trials,3,4 in which the 3-week regimen (40 Gy in 15 fractions or 42·5 Gy in 16 fractions) matched the tumour control of conventional fractionation with less late tissue effects. Thu, 14 May 2026 22:30:04 +0000
[Comment] [177Lu]Lu-dota-tate radioligand therapy for advanced pancreatic neuroendocrine tumours Radioligand therapy, commonly referred to as peptide receptor radionuclide therapy (PRRT), is an established and effective treatment for patients with advanced gastroenteropancreatic neuroendocrine tumours who have progressive disease after previous systemic therapy.1 Treatment selection in patients with progressive advanced gastroenteropancreatic neuroendocrine tumours is multifactorial and guided by primary site, hormonal functionality, symptom burden related to tumour volume, extent of metastatic disease, histological grade, and patient preference. Mon, 01 Jun 2026 00:00:00 -0700
[Comment] The global cancer workforce crisis: a shared responsibility, a united front The Lancet Oncology Commission on the cancer workforce1 presents a stark analysis of an impending global health catastrophe. The Commission projects a workforce shortage of nearly 100 million individuals by 2050. This shortage directly correlates with a widening survival gap between high-income countries (HICs) and low-income and middle-income countries (LMICs). By 2050, Africa's 5-year net survival rate could be nearly half that of HICs, a disparity directly linked to the lack of qualified health professionals. Sun, 31 May 2026 12:00:02 +0000
[Comment] Beyond the count: the unseen foundations of cancer care The Lancet Oncology Commission on the cancer workforce1 makes a case that governments, funders, and policy makers can no longer ignore. It elegantly reframes workforce investment—not as a development aspiration but as an economic imperative. However, a compelling case and a complete one are not always the same thing. Sun, 31 May 2026 12:00:02 +0000
[Comment] AI and the cancer workforce: what problem are we solving? The Lancet Oncology Commission on the cancer workforce1 arrives at a moment of mounting pressure on cancer systems worldwide. However, the workforce crisis is not only a question of numbers, it reflects deeper challenges in how care is organised, delivered, and experienced. Patients, families, and caregivers continue to describe systems that are fragmented, impersonal, and poorly equipped to care for the person beyond the disease. At the same time, burnout and moral injury among oncology professionals are rising, further deepening the workforce crisis. Sun, 31 May 2026 12:00:02 +0000
[Comment] From shortage to synergy: transforming global radiology workforce capacity with digital innovation and task-shifting Workforce disparities in cancer care represent one of the most profound and persistent inequities in global health, with low-income and middle-income countries (LMICs) bearing a disproportionate share of cancer mortality. While high-income countries (HIC) maintain a relatively high number of specialists involved in cancer care, many LMICs struggle with major shortages. This inequality is notably severe for diagnostic specialists, who are 15 times more prevalent in HICs than in low-income regions. Sun, 31 May 2026 12:00:02 +0000
[Comment] The UK's radiotherapy workforce shortage: a case for reform The Lancet Oncology Commission on the cancer workforce1 documents a global crisis in the cancer workforce defined by chronic undersupply, accelerating demand, and health systems increasingly unable to recruit and retain the specialists they need. The UK offers a pointed illustration of how domestic policy choices can compound this challenge. Sun, 31 May 2026 12:00:02 +0000
[Comment] Regionally anchored, globally connected: lessons from the Pacific on the cancer workforce crisis The Lancet Oncology Commission on the cancer workforce1 is a timely and important examination of the future unmet need for cancer health professionals, and the devastating fiscal and human cost of inaction. In many settings, this crisis is not looming; it has already arrived. Sun, 31 May 2026 12:00:02 +0000
[Correspondence] Brachytherapy capacity gaps and cancer control priorities Abdurrahman Hajeer and colleagues published findings from an observational study in which 708 948 cancers were estimated to have required brachytherapy across 185 countries in 2022 (3·8% of incident cases).1 Assuming 218 cases per centre annually, 2246 additional centres would be required by 2050. These findings highlight major inequities in access but do not determine priority setting for cancer control resources. Mon, 01 Jun 2026 00:00:00 -0700
[Correspondence] Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma We read with great interest the OligoPanc consensus by Carl-Stephan Leonhardt and colleagues.1 We congratulate the authors on this landmark interdisciplinary work, which represents the first international effort to standardise the definition of oligometastatic pancreatic ductal adenocarcinoma, and will help harmonise future clinical trials. Mon, 01 Jun 2026 00:00:00 -0700
[Correspondence] Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma – Authors' reply We thank Hector Prudhomme and colleagues for their interest in our Article describing a consensus definition of oligometastatic pancreatic ductal adenocarcinoma.1 Para-aortic lymph nodes are an important site of metastasis in pancreatic ductal adenocarcinoma and were therefore explicitly addressed, both in the Delphi process and in vignette three. Although 27 (82%) of 33 respondents to vignette three considered it oligometastatic pancreatic ductal adenocarcinoma, only 32 (56%) of 57 in the Delphi consensus classified para-aortic lymph node metastasis as oligometastasis, thereby meaning that the predefined 75% or greater consensus threshold was not reached. Mon, 01 Jun 2026 00:00:00 -0700
[Correspondence] On the survival benefit from sentinel node biopsy for melanoma We read with interest the systematic review and meta-analysis by Alexander H R Varey and colleagues1 assessing the potential survival benefit of sentinel node biopsy (SNB). We also recognise author John F Thompson for a long and accomplished career that successfully established SNB as a routine part of melanoma diagnostics. Mon, 01 Jun 2026 00:00:00 -0700
[Correspondence] On the survival benefit from sentinel node biopsy for melanoma – Authors' reply We thank Dirk J Grunhagen and colleagues for their interest in our systematic review. We agree that minimising bias is crucial in such studies. Although individual patient data were not available, the Review was rigorously conducted to minimise residual confounding and selection bias through careful study design and appropriate analyses. Mon, 01 Jun 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 614–24 Morgans AK, Haresh KP, Jievaltas M, et al. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2026; 27: 614–24—In this Article, the third sentence of the last paragraph of the Results section should have read “The most common grade 3–4 adverse events were hypertension (19 [4%] of 445 patients who received darolutamide vs eight [4%] of 221 patients who received placebo), anaemia (14 [3%] vs eight [4%]), and aspartate aminotransferase increase (ten [2%] vs one [<1%]).” This correction has been made to the online version as of June 1, 2026. Mon, 01 Jun 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: e238–47 Widder J, Bol GM, Simek I-M, et al. Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium. Lancet Oncol 2026; 27: e238–47—In this Policy Review, the table headings should have read “Frequency”. In the Declaration of interests section, statements have been corrected for Helena M Verkooijen and Luca Visani. These corrections have been made to the online version as of June 1, 2026. Mon, 01 Jun 2026 00:00:00 -0700
[News] Clinicians have no capacity to deliver on England's national cancer plan, think tank warns Clinicians in England do not have the capacity or headspace to do the innovation needed to deliver the Government's National Cancer Plan, a think tank has warned. Thu, 23 Apr 2026 22:30:01 +0000
[News] Air pollution and cancer in Thailand In Thailand, particularly in the northern provinces of the country (eg, Chiang Mai), sustained air pollution, mainly due to persistent wildfires and burning of agricultural waste by farmers, has led to a thick cloud of grey haze and substantial exposure to PM2·5, triggering surges in pollution-related illnesses including cancer. Thu, 30 Apr 2026 22:30:02 +0000
[News] US drinking water polluted with carcinogenic nitrates Almost a fifth of the US population are exposed to potentially cancer-causing nitrates through their drinking water, according to a recent analysis by the Environmental Working Group (EWG). Thu, 30 Apr 2026 22:30:01 +0000
[News] US Senate Bill aims to boost cancer trial enrolment and equity One in five cancer clinical trials in the USA fail due to insufficient patient enrolment, according to a report from the American Cancer Society Cancer Action Network. Recruitment challenges are pushing researchers overseas, where recruitment is often faster and less expensive, while many eligible US Americans—especially older adults, people from racially minoritised or minority ethnic populations, residents of low-income rural communities, and members of Indigenous communities—cannot afford to participate in potentially life-saving trials, largely because of travel expenses. Fri, 08 May 2026 22:30:01 +0000
[News] Radiation oncologists in the USA fight against policy changes On April 27, 2026, US radiation oncologists visited Capitol Hill to tell legislators that the recent policy changes in Medicare have threatened the sustainability of community cancer clinics in the country, as latest data suggested significant economic distress across the field. Thu, 14 May 2026 22:30:04 +0000
[News] ESTRO 2026 David Krug (University Hospital Schleswig-Holstein, Kiel, Germany) presented the first results from a randomised controlled trial showing a progression-free survival benefit from metastasis-directed therapy for patients with oligometastatic breast cancer. In the randomised controlled OLIGOMA trial, patients were randomly assigned to systemic therapy (n=44) or systemic therapy plus stereotactic body radiotherapy (SBRT) to metastatic lesions (n=43). Co-primary endpoints were progression-free survival and quality of life at 12 weeks. Thu, 21 May 2026 22:30:01 +0000
[News] Findings suggest under-reporting of patient data in US SEER Gaps in patient data reported to the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database by some rural, safety-net, and community hospitals could skew cancer rates and survival outcomes in studies of some of the most vulnerable patient populations. Patients treated at facilities not accredited by the American College of Surgeons Commission on Cancer were two to three times more likely to have missing clinical data in SEER patient records than those treated at Commission on Cancer-accredited centres, researchers reported. Thu, 21 May 2026 22:30:00 +0000
[Perspectives] Embedding equity in Germany's National Lung Cancer Screening roll-out: a call to action Lung cancer is the leading cause of cancer deaths, causing approximately 1.8 million deaths worldwide.1 Screening with low-dose CT (LDCT) has been shown to significantly reduce lung cancer-specific mortality among populations at high-risk by 20–26%.2 National lung cancer screening programmes have been implemented in several countries and will be introduced in Germany in 2026. Despite these advances, population-level implementation fails to adequately reach those at highest risk;3 globally, lung cancer screening programmes face persistent challenges in achieving equitable access across racial, ethnic, geographic, and socioeconomic groups. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial Aglatimagene plus valacyclovir was associated with longer disease-free survival than placebo plus valacyclovir when added to standard of radiotherapy for the treatment of localised prostate cancer, offering a meaningful benefit without increasing clinically significant toxicity. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy Long-term follow-up confirms that 26 Gy in five fractions over 1 week is safe and efficacious for adjuvant radiotherapy to the breast or chest wall, supporting its use as a standard of care. Efficacy data for this schedule in the axillary nodal radiotherapy setting are reassuring; however, sample size limits precision of estimation for this subgroup on its own. Thu, 14 May 2026 22:30:02 +0000
[Articles] [177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial Using sunitinib as an internal control, our results show clinically significant antitumour efficacy of [177Lu]Lu-dota-tate in pretreated, progressive, somatostatin receptor-positive, metastatic pancreatic neuroendocrine tumours, and a better quality of life during the treatment phase. Late adverse events were reported in the [177Lu]Lu-dota-tate group that might affect the tolerance of subsequent lines of treatment. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study Long-term follow-up supports the safety and local control of SABR for non-surgical patients with renal cell carcinoma, with no observed local recurrences or cancer-related deaths in this cohort, which had predominantly T1b disease or higher. Sun, 17 May 2026 09:40:01 +0000
[Articles] Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials This pooled analysis from two clinical trials of SABR in patients with larger primary kidney tumours unsuitable for surgery supports evidence of long-term local control and low rate of severe adverse events. These results support further investigation through a randomised trial comparing SABR with surgery in select operable patients. Sun, 17 May 2026 09:40:01 +0000
[Articles] MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial MRI-guided adaptation for glioblastoma enables margin de-escalation and resulted in a low rate of marginal failure. A randomised trial comparing this technique to a standard large-margin radiotherapy approach will establish whether toxicity and quality-of-life improvements can be realised. Thu, 14 May 2026 22:30:02 +0000
[Articles] International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study The pandemic's greatest impact was during the first few months of societal lockdowns in 2020 when barriers in access to health care were greatest. Further research is needed to understand whether patients with a missed diagnosis were diagnosed at a later date and if they presented at a later stage. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Real-world heart and lung doses from 30 000 National Health Service radiotherapy treatment plans in England: a national audit of breast radiotherapy practice This breast radiotherapy dosimetry audit shows the feasibility of high-quality large-scale, real-world dosimetric collection and evaluation across the NHS in England. Heart and lung doses predominantly met constraints and were comparable to international benchmarks. However, dosimetric variation existed between centres, particularly in volumetric-modulated arc therapy planning, identifying opportunities for quality improvement. Mon, 18 May 2026 15:00:02 +0000
[The Lancet Oncology Commission] Cancer workforce—a global crisis: a Lancet Oncology Commission The shortage of well-trained personnel to deliver cancer care and conduct research remains a major obstacle to reducing disparities in cancer survival between high-income countries and low-income and middle-income countries (LMICs). This Commission set out to provide actionable guidance for strengthening the global cancer workforce with an emphasis on reducing these disparities. To better understand the extent of the rising global cancer burden and the resulting workforce needs, we modelled the current and future global landscape of 17 common cancers and 18 workforce personnel types. Sun, 31 May 2026 12:00:02 +0000
|
Magnetic resonance imaging‐targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial
TB + iSB met the prespecified noninferiority criterion for csPCa detection relative to TB + SB and may represent a promising core‐reduction strategy in transperineal MRI‐guided biopsy, although the full protocol still provided additional contralateral information. Fri, 19 Jun 2026 05:24:29 -0700 Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib The addition of olaparib to radium‐223 was not associated with significant detriment to PROs or pain, which supports the tolerability of this combination. Fri, 19 Jun 2026 05:22:31 -0700 Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study Selinexor combined with azacitidine or ruxolitinib showed encouraging efficacy with a manageable safety profile in patients with MDS/MPN. Fri, 19 Jun 2026 04:13:25 -0700 Issue Information Fri, 19 Jun 2026 03:28:55 -0700 |
||
|
| |||
|
[Editorial] Closing the sickle cell disease-related health equity gap
June 19, marks World Sickle Cell Day, with the 2026 theme focusing on closing the survival gap and a push towards a universal cure. 20 years have passed since the WHO recognised sickle cell disease as a global health problem, and although some progress has been made, there is clearly still substantial work to be done to improve outcomes for those living with the disease around the world. Mon, 01 Jun 2026 00:00:00 -0700
[Comment] Beyond biomarkers: tissue still matters The diagnosis of primary CNS lymphoma has traditionally relied on stereotactic brain biopsy, while cytological analysis of cerebrospinal fluid (CSF) or vitreous humour is diagnostic in only a minority of patients.1 Although essential for histopathological confirmation, brain biopsy carries inherent risks, with mortality rates ranging from 0·8% to 2·2%, and might cause substantial delays in treatment initiation.1 Consequently, the development of reliable, less invasive diagnostic approaches has become a major objective in the management of primary CNS lymphoma. Mon, 01 Jun 2026 00:00:00 -0700
[Comment] Artificial intelligence triage tool for bone marrow fibrosis in myeloproliferative neoplasms using complete blood counts Bone marrow examination is integral to the diagnosis and classification of myeloproliferative neoplasms, but is invasive, can be technically challenging, and is not always immediately feasible. Marie Donzel and colleagues present the Fibrosis Prediction in Bone Marrow using Artificial Intelligence (FIBOM-AI) model,1 a machine learning model trained to predict grade 2–3 bone marrow fibrosis using only age and routine complete blood count (CBC) parameters. Developed from a multicentre cohort using data from 1995 patients with a suspected or established myeloproliferative neoplasm across 13 French centres, and evaluated with both external and prospective validation, this study offers a practical example of how artificial intelligence (AI) can extract insights from routine, inexpensive laboratory data. Mon, 01 Jun 2026 00:00:00 -0700
[Comment] Global roadmap for stroke in sickle cell disease: an urgent call to action on an overlooked burden Sickle cell disease is one of the most common severe hereditary disorders worldwide. More than 500 000 infants are born with sickle cell disease each year, the majority in sub-Saharan Africa, where early diagnosis and comprehensive care remain limited.1 Advances in neonatal screening and infection prevention have improved survival, but this success has also exposed the growing lifetime burden of cerebrovascular disease.1 Stroke is a leading cause of morbidity, cognitive impairment, and disability in sickle cell disease. Mon, 01 Jun 2026 00:00:00 -0700
[Correspondence] A call to embrace qualitative research in haematology journals We write as an international group of qualitative researchers working within haematology. We commend Prasanna Ananth and colleagues for their expert recommendations on conducting and appraising qualitative research, including five pillars that support best practice in qualitative studies.1 Quantitative research can tell us what and how much, but qualitative and mixed methods studies help explain why. These approaches are essential for creating and evaluating interventions that work in real-world contexts. Mon, 01 Jun 2026 00:00:00 -0700
[In Focus] The library “Where is Talal?” one of the fellows asked.“Probably in the library” another replied with a chuckle. Mon, 01 Jun 2026 00:00:00 -0700
[In Focus] Functional time in chronic lymphocytic leukaemia Chronic lymphocytic leukaemia is often described as indolent—a leukaemia that unfolds slowly, sometimes over decades. In older adults, it behaves less like an acute malignancy and more like a chronic companion. Many patients are diagnosed incidentally and require no immediate therapy. The biology might be calm but the lived experience rarely is. Mon, 01 Jun 2026 00:00:00 -0700
[In Focus] Ayako Arai: 25 years dedicated to a rare but devastating condition When Ayako Arai was at medical school in the late 1980s, she became fascinated with the “extraordinary beauty” of blood cells under a microscope. At the time, haematopoietic stem-cell transplantation (HSCT) was just becoming established and the concept of molecular targeted therapy beginning to emerge. Mon, 01 Jun 2026 00:00:00 -0700
[In Focus] You Look Fine “You Look Fine” begins with LA-based comedian Jared “J” Snow trying a bit of boxing. His trainer holds the mitts and calls the combinations. Jab, right, hook, right, roll, finish with another right. J lands punches, moves competently around the ring, and rests when the bell sounds. After three rounds, he starts feeling discomfort in his chest, so he stops training and goes home to bathe in Epsom salts and swallow some painkillers. He hopes this will be enough to forestall a sickle cell crisis. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Total marrow and lymphoid irradiation in combination with cyclophosphamide and etoposide before haematopoietic cell transplantation for relapsed or refractory acute leukaemia: a single-centre, open-label, phase 2 trial Adverse events were few, probably due to organ sparing by total marrow and lymphoid irradiation. Total marrow and lymphoid irradiation 2000 cGy could be safely delivered in combination with high-dose etoposide and cyclophosphamide. The regimen was associated with encouraging 2-year progression-free survival rates. Mon, 18 May 2026 22:30:02 +0000
[Articles] Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study In this prospective, multicentre cohort of patients with suspected primary CNS lymphoma, we validated the high diagnostic value of MYD88, IL-10, and CXCL13. Results should be interpreted within the full clinical context and with caution, as the diagnostic algorithm and decision tree were derived within the same cohort. In selected clinical scenarios and with further validation of these results, combined CSF biomarker testing might support non-invasive diagnostic decision making and reduce reliance on brain biopsy. Mon, 01 Jun 2026 00:00:00 -0700
[Articles] Post pulmonary embolism syndrome following paediatric pulmonary embolism: a multicentre, retrospective cohort study This study showed a high prevalence of post pulmonary embolism syndrome in children with pulmonary embolism. Different clinical factors can contribute, including psychological distress factors and physical limitations, emphasising the need for comprehensive, multidisciplinary care. Wed, 20 May 2026 22:30:01 +0000
[Articles] Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study FIBOM-AI can be reliably used as a triage and prioritisation tool to support timely bone marrow evaluation or provide complementary risk assessment when bone marrow biopsy is not immediately feasible. Mon, 01 Jun 2026 00:00:00 -0700
[Review] Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee Donor cell-derived haematological neoplasms (DDHN) are rare disorders and currently do not have standardised diagnostic criteria and therapeutic management. International experts in allogeneic transplantation and haematological malignancies from Europe, the Americas, and Australia worked together on behalf of the EBMT Practice Harmonisation and Guidelines Committee to delineate a pragmatic diagnostic framework and issue guidance for downstream clinical management for DDHN. The team met on Sept 18–19, 2025, in Berlin, Germany, to discuss the definition, molecular insights, treatments, and donor outcomes for DDHN after an intensive review of the literature. Mon, 01 Jun 2026 00:00:00 -0700
[Review] A novel US-based grading system for disease severity in sickle cell disease: the Sickle Cell Outcome Grading System (SCOGS) Sickle cell disease is a haematological disorder marked by recurrent events and progressive organ dysfunction, yet a standardised framework to assess disease severity is lacking. We developed a novel US-based severity grading system through identification of sickle cell disease-related complications mapping all to the Common Terminology Criteria For Adverse Events and applying a five-level severity scale. A modified Delphi process involving 29 US-based sickle cell disease experts was conducted over three virtual rounds (from Oct 20 to Nov 8, 2023; from June 26 to Aug 1, 2024; and from Nov 6, 2024, to Jan 7, 2025), with the use of a 9-point Likert scale ratings and iterative feedback. Mon, 01 Jun 2026 00:00:00 -0700
[Clinical Picture] Double trouble: sequential lymphomas An 83-year-old woman presented to our haematology department in June, 2025, with a 3-month history of palpable cervical lymphadenopathy and splenomegaly. Contrast-enhanced CT revealed enlarged cervical, axillary, inguinal, and visceral lymphadenopathy. A biopsy of a cervical lymph node verified a diagnosis of stage IV angioimmunoblastic T-cell lymphoma (AITL; appendix pp 3–4). Immunohistochemistry showed atypical T cells positive for CD3, CD4, CD10, CD30, ICOS, BCL6, and PD1. In-situ hybridisation for Epstein–Barr virus (EBV)-encoded RNA (EBER) testing was negative (appendix p 7). Mon, 01 Jun 2026 00:00:00 -0700
|
Frontline CLL: lessons from the final analysis of CLL13-GAIA
Volume 147, Issue 25 June 18 2026 Monocytes matter: prognostic impact in clonal hematopoiesis Volume 147, Issue 25 June 18 2026 Less is more in primary cutaneous indolent B-cell lymphoma Volume 147, Issue 25 June 18 2026 The RELEVANCE of long-term follow-up in follicular lymphoma Volume 147, Issue 25 June 18 2026 Signal AML stem cells to home: written and sent by METTL1 Volume 147, Issue 25 June 18 2026 The clot stiffens: neutrophil serpin B3 in ischemic stroke Volume 147, Issue 25 June 18 2026 Platelets under pressure: a sticky outside-in problem Volume 147, Issue 25 June 18 2026 Ticks and transfusions: a potentially fatal mix! Volume 147, Issue 25 June 18 2026 Immune-mediated side effects of cancer immunotherapies Although immunotherapies such as allogeneic hematopoietic cell transplantation and infusion of chimeric antigen receptor T (CAR-T) cells can provide substantial therapeutic benefit, they are also associated with severe immune-mediated toxicities. Braun, Naidoo, and Zeiser review the similarities and differences among acute graft-versus-host disease, immune toxicities following CAR-T cell infusion, and immune-related adverse events associated with checkpoint inhibition. They also propose a framework for developing strategies that target shared mechanisms underlying these toxicities, with the goal of reducing the immune-mediated side effects of cancer immunotherapies.
Volume 147, Issue 25 June 18 2026 Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial The pivotal phase 3 GAIA/CLL13 trial evaluated 3 venetoclax-based combinations as first-line treatment for fit patients with chronic lymphocytic leukemia (CLL) compared with standard chemoimmunotherapy. In a 5-year follow up, Fürstenau et al report that venetoclax-obinutuzumab-ibrutinib significantly prolonged progression-free survival versus all other treatments while also reducing treatment discontinuations and cardiac adverse events. These results establish the superiority of venetoclax-based regimens over chemoimmunotherapy in frontline CLL therapy and confirm obinutuzumab as a more effective antibody partner than rituximab. Important questions remain regarding the optimal balance of efficacy and toxicity, the choice of Bruton tyrosine kinase inhibitor as a partner, and which patients benefit most from doublet approaches versus triplet approaches.
Volume 147, Issue 25 June 18 2026 The prevalence and clinical significance of clonal monocytosis The terms clonal monocytosis of undetermined significance (CMUS) and clonal cytopenia and monocytosis of undetermined significance (CCMUS) were introduced to describe clonal hematopoiesis accompanied by monocytosis. Dunn et al leveraged a large UK Biobank cohort to demonstrate that CMUS with absolute monocytosis and CCMUS are high-risk entities strongly associated with incident myeloid neoplasia, as well as cardiovascular and renal disease, and they corroborated these findings in an independent Danish cohort. This report underscores the clinical relevance of CMUS and CCMUS as distinct high-risk states within the spectrum of clonal hematopoiesis.
Volume 147, Issue 25 June 18 2026 Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis The effectiveness and safety of radiation therapy for early-stage primary cutaneous indolent B-cell lymphomas remain unclear. Oertel et al report a large retrospective international study of more than 500 patients with primary cutaneous follicular center lymphoma or primary cutaneous marginal zone lymphoma treated with radiotherapy. Radiotherapy achieved complete response rates exceeding 90%, with higher doses (>4 Gy) associated with longer response duration but increased toxicity. These findings support the excellent prognosis of these lymphomas and emphasize the importance of using minimal effective radiotherapy doses to avoid overtreatment.
Volume 147, Issue 25 June 18 2026 Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis The combination of rituximab and lenalidomide provides a chemotherapy-free option for patients with untreated follicular lymphoma (FL). In this month’s CME article, Gower et al report the 10-year follow-up of the phase 3 RELEVANCE trial, confirming that rituximab plus lenalidomide and standard immunochemotherapy achieve comparable efficacy and safety outcomes. These findings provide important information to aid clinicians and patients with previously untreated advanced FL choosing a treatment regimen.
Volume 147, Issue 25 June 18 2026 Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia Volume 147, Issue 25 June 18 2026 Pathogenic role of serpin B3-positive neutrophils in reinforcing thrombus stiffening during ischemic stroke The etiology of clot stiffening, which contributes to resistance to both lytic agents and thrombectomy devices in acute ischemic stroke, remains unclear. Zang et al combined multiplex imaging and spatial proteomics of clinical thrombus samples with functional in vitro assays and translational in vivo models to identify a neutrophil-driven serpin B3–transforming growth factor β1 signaling axis that promotes collagen deposition, progressive thrombus stiffening, and resistance to thrombolytic therapy. In a mouse model, inhibition of serpin B3 improved neurological recovery, raising the possibility that modulation of this pathway could be tested clinically.
Volume 147, Issue 25 June 18 2026 A novel G13-RAPGEF2-RAP1 signaling pathway critical for platelet adhesion and aggregation RAPGEF2 is the second most highly expressed guanine nucleotide exchange factor for RAP1, a small GTPase, which is critical for platelet integrin activation and aggregation. Paul et al used murine models to characterize the contribution of RAPGEF2 signaling to platelet function, hemostasis, and thrombosis, showing that it operates between G13-coupled receptors and RAP1 in platelets to support platelet adhesion, particularly under conditions of shear stress. These findings improve our understanding of G-protein signaling and integrin function in platelets and suggest potential platelet-targeted therapies for cardiovascular disease.
Volume 147, Issue 25 June 18 2026 Severe allergic transfusion reactions to group B/AB plasma or platelets in group O recipients are linked to α-Gal sensitization Group O recipients of group B or AB blood components have a significantly higher risk of severe allergic transfusion reactions than recipients with other combinations. De Chaisemartin et al evaluated whether this risk is associated with sensitization to the galactose-α-1,3-galactose (α-Gal) epitope, which is typically acquired after exposure to the glycan through tick bites. They show that group O patients who experience severe allergic reactions to group B or AB blood components are substantially more likely to have anti–α-Gal immunoglobulin E antibodies than patients with other donor-recipient combinations. If confirmed in larger studies, these findings could have important implications for transfusion practices.
Volume 147, Issue 25 June 18 2026 Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial A recent phase 3 trial showed that nivolumab combined with doxorubicin, vinblastine, and dacarbazine (N-AVD) improves 3-year progression-free survival in patients with advanced-stage Hodgkin lymphoma. Robertz et al now report that gonadal hormone levels remained stable for up to 24 months after N-AVD in a separate phase 2 trial. Although these findings suggesting preserved gonadal function and fertility are encouraging, they require confirmation with larger cohorts and longer follow-up.
Volume 147, Issue 25 June 18 2026 Multinucleated plasma cells and IgG λ myeloma in a patient with TEMPI syndrome and renal cell carcinoma Volume 147, Issue 25 June 18 2026 Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147(18):2041-2052. Volume 147, Issue 25 June 18 2026 The 10-year RELEVANCE trial analysis Volume 147, Issue 25 June 18 2026 |
Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Mon, 15 Jun 2026 21:00:19 -0700 Promoter TERT‐Related Hematopoietic Somatic Mosaicism in Patients With Telomere Biology Disorders Mon, 15 Jun 2026 03:56:10 -0700 Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third‐Line or Later Relapsed/Refractory Multiple Myeloma Fri, 12 Jun 2026 21:16:43 -0700 A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma Fri, 12 Jun 2026 03:31:04 -0700 Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome Wed, 10 Jun 2026 23:15:13 -0700 CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib‐Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET‐CT Tue, 09 Jun 2026 20:56:03 -0700 Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents Mon, 08 Jun 2026 00:00:00 -0700 Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia Sun, 07 Jun 2026 22:46:19 -0700 Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”? Sun, 07 Jun 2026 22:03:34 -0700 Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma Sun, 07 Jun 2026 22:01:35 -0700 Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents Sun, 07 Jun 2026 20:56:40 -0700 Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis Sun, 07 Jun 2026 20:54:57 -0700 Response to Methodological Concerns Regarding Eligibility Criteria and Study Selection in a Systematic Review and Meta‐Analysis of CAR T‐Cell Therapy for Hematologic Malignancies Fri, 05 Jun 2026 02:46:16 -0700 Therapeutic Silencing of Tmprss6 Reduces Iron‐Induced Inflammation and Prolongs Survival in MDS Mice Thu, 04 Jun 2026 03:57:44 -0700 Development and Validation of a Novel Conditional Event‐Free Survival Tool in Diffuse Large B‐Cell Lymphoma Thu, 04 Jun 2026 03:43:02 -0700 Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia Wed, 03 Jun 2026 21:37:28 -0700 Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I‐WISh) 2.0 Wed, 03 Jun 2026 21:36:15 -0700 Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study Wed, 03 Jun 2026 21:11:15 -0700 JAKPOT Prediction Rule for Erythrocytosis: External Validation and Cost‐Effectiveness Analysis Tue, 02 Jun 2026 02:00:43 -0700 Compound Heterozygosity for Hemoglobin S and Hemoglobin LuLu Island Tue, 02 Jun 2026 00:47:02 -0700 Somatic Mutations in Acquired Pure Red Cell Aplasia: Incidence and Implications Tue, 02 Jun 2026 00:47:02 -0700 |
|
|
| |||
|
CAR in R/R FL: is real-world efficacy meeting expectations? June 9 2026 - Volume 10, Issue 11 Interferon in early MF: intersection of biology and evidence June 9 2026 - Volume 10, Issue 11 Real-world experience with tabelecleucel June 9 2026 - Volume 10, Issue 11 Are CHOP-plus really CHOP-minus propositions in the treatment of PTCL? A comprehensive assessment of the strategy June 9 2026 - Volume 10, Issue 11 Management of relapsed/refractory AL amyloidosis June 9 2026 - Volume 10, Issue 11 Conventional therapy vs HMA or LDAC with or without venetoclax in older adults with AML: systematic review and meta-analysis June 9 2026 - Volume 10, Issue 11 Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review and meta-analysis June 9 2026 - Volume 10, Issue 11 FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial June 9 2026 - Volume 10, Issue 11 A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation June 9 2026 - Volume 10, Issue 11 Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma June 9 2026 - Volume 10, Issue 11 Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction June 9 2026 - Volume 10, Issue 11 Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia June 9 2026 - Volume 10, Issue 11 Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy June 9 2026 - Volume 10, Issue 11 Cure Sickle Cell Initiative recommendations on common data elements for sickle cell disease gene therapy trials June 9 2026 - Volume 10, Issue 11 Targeted LNP-mediated delivery of VE-cadherin mRNA reduces vascular hyperpermeability in vivo June 9 2026 - Volume 10, Issue 11 Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy June 9 2026 - Volume 10, Issue 11 Real-world experience with tabelecleucel within and beyond the approval label June 9 2026 - Volume 10, Issue 11 Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study June 9 2026 - Volume 10, Issue 11 Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma June 9 2026 - Volume 10, Issue 11 Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma June 9 2026 - Volume 10, Issue 11 Digital spatial profiling uncovers transcriptomic features of distinct plasma cell–like phenotypes in diffuse large B-cell lymphoma June 9 2026 - Volume 10, Issue 11 IL-6–driven POU2AF1 and ELL2 are key regulators of multiple myeloma–distinct transcriptional and splicing programs June 9 2026 - Volume 10, Issue 11 Idecabtagene vicleucel manufacturing and clinical value of out-of-specification products in relapsed and refractory MM June 9 2026 - Volume 10, Issue 11 MSLN expression predicts a high risk of EMD in AML by promoting cell adhesion and metastasis via interaction with MUC16 June 9 2026 - Volume 10, Issue 11 Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis June 9 2026 - Volume 10, Issue 11 Effectiveness of health care transition interventions for sickle cell disease June 9 2026 - Volume 10, Issue 11 Transthyretin V122I variant and protein affect cardiac severity and mortality in sickle cell disease June 9 2026 - Volume 10, Issue 11 Accurate identification of sickle cell disease cases in a large genotyped cohort using electronic health record data June 9 2026 - Volume 10, Issue 11 TFPIα inhibition by andexanet alfa is partially restored by protein S and factor V-short June 9 2026 - Volume 10, Issue 11 Cystic fibrosis and sickle cell disease associated with nonadministration of VTE prophylaxis in hospitalized adults June 9 2026 - Volume 10, Issue 11 Telomere length and clonal hematopoiesis interact to influence outcomes in hematopoietic stem cell transplantation June 9 2026 - Volume 10, Issue 11 A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation June 9 2026 - Volume 10, Issue 11 No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12 June 9 2026 - Volume 10, Issue 11 AR expression in AML cells is same in female vs male patients June 9 2026 - Volume 10, Issue 11 Similar androgen receptor expression in male and female AML June 9 2026 - Volume 10, Issue 11 Zhang B, Xie Y, Shen M, et al. Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma. Blood Adv. 2025;9(13):3249-3262. June 9 2026 - Volume 10, Issue 11 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia
New England Journal of Medicine, Volume 394, Issue 23, Page 2329-2339, June 18, 2026.
Prehospital Whole Blood in Traumatic Hemorrhage — A Randomized Controlled Trial New England Journal of Medicine, Volume 394, Issue 23, Page 2305-2316, June 18, 2026.
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial New England Journal of Medicine, Volume 394, Issue 23, Page 2293-2304, June 18, 2026.
Management of Differentiated Thyroid Cancer New England Journal of Medicine, Volume 394, Issue 23, Page 2340-2355, June 18, 2026.
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer New England Journal of Medicine, Volume 394, Issue 23, Page 2382-2383, June 18, 2026.
Intravenous Artesunate in Artemisinin-Resistant Severe Malaria in Uganda New England Journal of Medicine, Volume 394, Issue 23, Page 2380-2382, June 18, 2026.
Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy New England Journal of Medicine, Volume 394, Issue 23, Page 2384-2384, June 18, 2026.
Stenting for Post-Thrombotic Syndrome — A Step Forward New England Journal of Medicine, Volume 394, Issue 23, Page 2370-2371, June 18, 2026.
Immunosuppression-Associated Peripheral T-Cell Lymphoma New England Journal of Medicine, Volume 394, Issue 23, Page 2356-2356, June 18, 2026.
Case 17-2026: A 74-Year-Old Man with Pancytopenia New England Journal of Medicine, Volume 394, Issue 23, Page 2357-2368, June 18, 2026.
“In One Year, I Want You Alive” New England Journal of Medicine, Volume 394, Issue 23, Page 2289-2291, June 18, 2026.
The Convergence of Down Syndrome and Alzheimer’s Disease — Scientific and Ethical Imperatives New England Journal of Medicine, Volume 394, Issue 23, Page 2286-2289, June 18, 2026.
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis New England Journal of Medicine, Ahead of Print.
Iptacopan in IgA Nephropathy — Final 24-Month Data New England Journal of Medicine, Ahead of Print.
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy New England Journal of Medicine, Ahead of Print.
Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock New England Journal of Medicine, Ahead of Print.
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis New England Journal of Medicine, Ahead of Print.
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy New England Journal of Medicine, Ahead of Print.
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia New England Journal of Medicine, Ahead of Print.
Perioperative Apalutamide in High-Risk Localized Prostate Cancer New England Journal of Medicine, Ahead of Print.
Obexelimab for the Treatment of IgG4-Related Disease New England Journal of Medicine, Ahead of Print.
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations New England Journal of Medicine, Ahead of Print.
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy New England Journal of Medicine, Ahead of Print.
Conservative Oxygen for Unresponsive Patients after Cardiac Arrest New England Journal of Medicine, Ahead of Print.
Carbocisteine or Hypertonic Saline for Acute Respiratory Failure New England Journal of Medicine, Ahead of Print.
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma New England Journal of Medicine, Ahead of Print.
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus New England Journal of Medicine, Ahead of Print.
Clusters of Concern — Spatial Link between Childhood Undervaccination and Measles Outbreaks in South Carolina New England Journal of Medicine, Ahead of Print.
Clinical Long-Read Genome Sequencing for Rare-Disease Diagnostics New England Journal of Medicine, Ahead of Print.
Sirolimus-Eluting Technology for the Treatment of Peripheral Artery Disease New England Journal of Medicine, Ahead of Print.
A Major Step toward a Cure for Hepatitis B Infection New England Journal of Medicine, Ahead of Print.
A Watershed Moment in the Perioperative Treatment of Prostate Cancer New England Journal of Medicine, Ahead of Print.
TRACTION for Greater Surgical Use of Tranexamic Acid New England Journal of Medicine, Ahead of Print.
The Social Contract of Bundibugyo Ebola Isolation New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
|
Ki-67 as a treatment decision modifier in breast cancer
Volume 31, Issue 7, July 2026, oyag183 CANLead: Canada as a Phase 1 Clinical Trial Leader — Opportunities, Initiatives, and Collaborative Innovation to Elevate National Competitiveness Volume 31, Issue 7, July 2026, oyag190 Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort Volume 31, Issue 7, July 2026, oyag158 Survival benefit of oral systemic monotherapy in previously treated metastatic colorectal cancer: a meta-analysis Volume 31, Issue 7, July 2026, oyag175 The emerging role of prostate-specific membrane antigen–targeted radioligand therapy in metastatic hormone-sensitive prostate cancer Volume 31, Issue 7, July 2026, oyag173 From prevention to progression: can belzutifan-based strategies deliver across the RCC disease continuum? Volume 31, Issue 7, July 2026, oyag193 Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer Volume 31, Issue 7, July 2026, oyag211 The association between financial toxicity and mortality in hematologic malignancies: a systematic review and meta-analysis Volume 31, Issue 7, July 2026, oyag178 Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study Volume 31, Issue 7, July 2026, oyag201 Efficacy and safety of tocilizumab for neoplastic fever in patients with advanced solid tumors: a multicenter retrospective study Volume 31, Issue 7, July 2026, oyag192 Patient-specific 3D-printed HDR surface brachytherapy for basal cell carcinoma in older patients: prospective feasibility and imaging response Volume 31, Issue 7, July 2026, oyag206 Daddy is dead: a physician reckons with her father’s mortality Volume 31, Issue 7, July 2026, oyag210 Dynamic therapeutic response to osimertinib and immunotherapy in an EGFR L747S and L858R co-mutant NSCLC Volume 31, Issue 7, July 2026, oyag227 Skin health in oncology: evidence-based skin care for cancer patients Volume 31, Issue 7, July 2026, oyag194 In reply to Topkan et al. Volume 31, Issue 7, July 2026, oyag195 |
Digital Therapeutics for Fecal Incontinence: What Real-World Data Can Support, and What It Cannot Diseases of the Colon & Rectum.69(6):1663-1665, June 2026. Reinterpreting Outcomes Following Different Neoadjuvant Treatment Approaches for Locally Advanced Rectal Cancer: Perspectives of the Discerning Reader Diseases of the Colon & Rectum.69(6):1666-1670, June 2026. Rupert B. Turnbull Jr, M.D., and Norma N. Gill: Founders of Enterostomal Therapy Diseases of the Colon & Rectum.69(6):1671-1678, June 2026. Rethinking Intestinal Stem Cells: Why Fgfbp1+ Progenitors Might Be More Critical Than the Lgr5+ Population Diseases of the Colon & Rectum.69(6):1679-1681, June 2026. Ulcerative Colitis-Associated Neoplasia Diseases of the Colon & Rectum.69(6):1682-1686, June 2026. Expert Commentary on Ulcerative Colitis–Associated Neoplasia Diseases of the Colon & Rectum.69(6):1687, June 2026. Textbook Outcome After IPAA for Ulcerative Colitis: A Nationwide Multicenter Study and Its Implications for Long-term Quality of Life Diseases of the Colon & Rectum.69(6):1688-1696, June 2026. Short-term Surgical Outcomes After Transanal Restorative Proctocolectomy With IPAA: A Comparison of Close Rectal Dissection and Modified Total Mesorectal Excision Diseases of the Colon & Rectum.69(6):1697-1701, June 2026. Tumor Necrosis Factor Alpha Inhibitors Reduce Staged Surgery Rate and Prevent Postoperative Endoscopic Recurrence in Patients With Crohn’s Disease Diseases of the Colon & Rectum.69(6):1702-1711, June 2026. A Digital Therapeutic Pelvic Health System Improves Fecal Incontinence Symptoms in a Real-World Patient Cohort Diseases of the Colon & Rectum.69(6):1712-1721, June 2026. Clinician and Patient Stakeholders Prioritize Rectal Prolapse Research Themes Through an International Delphi Process Diseases of the Colon & Rectum.69(6):1722-1731, June 2026. “Nobody Told Me”: A Qualitative Study of Sexual and Reproductive Concerns After Treatment for Early-Onset Colorectal Cancer Diseases of the Colon & Rectum.69(6):1732-1740, June 2026. Urinary Function After Laparoscopic Surgery in Very Low Rectal Cancer Diseases of the Colon & Rectum.69(6):1741-1748, June 2026. Influence of Circular Stapler Size and Number of Linear Stapler Firings on Anastomotic Leakage in Colorectal Surgery: A Retrospective Analysis of 1491 Patients Diseases of the Colon & Rectum.69(6):1749-1755, June 2026. Financial Toxicity Following Locally Advanced Rectal Cancer Treatment Diseases of the Colon & Rectum.69(6):1756-1765, June 2026. A Critical Appraisal of Colorectal Surgery Fellowship Standardized Letters of Recommendations Using Objective Criteria Diseases of the Colon & Rectum.69(6):1766-1771, June 2026. Selected Abstracts Diseases of the Colon & Rectum.69(6):1772-1776, June 2026. Robotic Splenic Flexure Colectomy With End-To-End Handsewn Anastomosis Diseases of the Colon & Rectum.69(6):1777, June 2026. Robotic-Assisted Reversal of Hartmann’s Procedure With Retroileal Tunnel of the Transverse Colon Diseases of the Colon & Rectum.69(6):1778, June 2026. Robotic Extended Left Colectomy With Colorectal Anastomosis Via Retroileal Window Diseases of the Colon & Rectum.69(6):1779-1780, June 2026. |
|
|
| |||
|
New ACSM Expert Consensus Statement: Exercise in Children and Adolescents With Cancer
In children and adolescents undergoing cancer treatment, exercise can be performed safely during and after therapy when appropriately supervised and individualized; further, appropriately prescribed exercise should be included as part of supportive cancer care, according to a new American College... Wednesday, June 17, 2026 10:00 AM Preclinical Research Shows IFN-γ May Attenuate Neutrophil Response to Cancer Immunotherapy Researchers have discovered that the type II interferon, interferon-γ, may impact how neutrophils react to immunotherapy, either supporting or blocking the treatment for patients with cancer, according to study findings published in Immunity. Wednesday, June 17, 2026 11:45 AM Low-Dose Tamoxifen in Noninvasive Breast Neoplasia In a long-term individual patient-level pooled analysis reported in the Journal of Clinical Oncology, Gandini et al found that low-dose tamoxifen was associated with good outcomes in patients with noninvasive breast neoplasia. Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab Patients with multiple myeloma who received a new immunotherapy combination had significantly longer progression-free survival and showed early signs of improved overall survival, according to findings from the phase III MonumenTAL-3 trial. Wednesday, June 17, 2026 10:00 AM FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic... Friday, June 12, 2026 4:47 PM PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer Adding the androgen receptor pathway inhibitor apalutamide to androgen-deprivation therapy (ADT) before and after radical prostatectomy significantly improves outcomes for patients with localized high-risk prostate cancer, according to findings from the phase III PROTEUS trial presented during the... Monday, June 1, 2026 10:54 AM Neoadjuvant Sacituzumab Govitecan in MIBC In an Italian phase II trial (SURE-01) reported in the Journal of Clinical Oncology, Necchi et al found that neoadjuvant sacituzumab govitecan was active in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for or elected not to receive neoadjuvant chemotherapy. Thyroid Cancer: Reproductive Lifespan, Hormone Therapy Potentially Linked to Incidence Longer exposure to hormone replacement therapy and longer reproductive lifespan showed potential associations with increased thyroid cancer risk in women, according to findings presented at ENDO 2026 (Abstract ORF12-08). Tuesday, June 16, 2026 1:00 PM Two-Pronged Nudges Result in Timely Conversations Around Priorities of Cancer Care Small, targeted reminders for both clinicians and patients to have serious illness conversations led to a significant increase in the number of conversations recorded, allowing for oncologists to better honor patients' goals and wishes for their cancer care, according to findings of a randomized... Tuesday, June 16, 2026 1:00 PM MIBC: Intravesical Recombinant BCG and Chemoimmunotherapy In a Swiss phase II trial (SAKK 06/19) reported at the 2026 ASCO Annual Meeting (Abstract 4503) and published in the Journal of Clinical Oncology, Cathomas et al found that the addition of intravesical recombinant bacillus Calmette-Guérin (rBCG) to perioperative chemoimmunotherapy was associated... Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC New findings from the phase III HARMONi-6 trial presented at the 2026 ASCO Annual Meeting showed that the investigational bispecific antibody ivonescimab combined with chemotherapy significantly improved overall survival compared with tislelizumab plus chemotherapy in patients with advanced... Monday, June 1, 2026 11:08 AM Metastatic Colorectal Cancer: GUCY2C-Targeted CAR T-Cell Therapy In a Chinese phase I dose-escalation and dose-expansion study reported in the Journal of Clinical Oncology, Qi et al found that guanylyl cyclase 2C (GUCY2C)-targeted chimeric antigen receptor (CAR) T-cell therapy had an “acceptable” safety profile and was active in patients with previously treated... Lu-177 Dotatate in Metastatic Pancreatic Neuroendocrine Tumors In a French phase II noncomparative trial (OCLURANDOM) reported in The Lancet Oncology, Baudin et al found that lutetium Lu-177 dotatate (Lu-177 dotatate) produced numerically better progression-free survival results than those achieved with sunitinib when used as an internal control in patients... Long-Term Outcomes of Adjuvant Hypofractionated Radiotherapy for Breast Cancer As reported in The Lancet Oncology by Brunt et al, long-term follow-up of the UK phase III FAST-Forward trial has shown that a 1-week adjuvant radiotherapy schedule was associated with good outcomes at 10 years in patients with breast cancer. Machine Learning Model May Improve Accuracy of Liquid Biopsy Results A machine learning model developed by researchers at the Johns Hopkins Kimmel Cancer Center filters out the biological noise in liquid biopsy samples, helping clinicians better match therapies to their patients’ tumors. These findings were published by Canzoniero et al in Clinical Cancer Research. Friday, June 12, 2026 10:43 AM Renal Cell Carcinoma: FDA Approves Adjuvant Belzutifan With Pembrolizumab Today, the U.S. Food and Drug Administration (FDA) approved the hypoxia-inducible factor-2 alpha inhibitor belzutifan (Welireg) in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of adults with renal cell... Friday, June 12, 2026 1:52 PM FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer On May 22, the U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Datroway), an antibody-drug conjugate targeting trophoblast cell surface antigen 2 (TROP2), for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for ... Friday, May 22, 2026 11:39 AM TP53 Mutation Acquisition Timing Influences Prognosis in MPNs, Study Finds The timing of TP53 mutation acquisition carries important prognostic implications for patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes/MPN overlap disorders. Later emergence of the mutation is associated with significantly worse survival outcomes, according to a... Friday, June 12, 2026 12:08 PM Novel Gene Therapy–Radiotherapy Combination in Localized Prostate Cancer As reported in The Lancet Oncology by DeWeese et al, the phase III PrTK03 trial has shown improved disease-free survival with the addition of aglatimagene besadenovec (aglatimagene) to valacyclovir in patients receiving standard radiation therapy for localized prostate cancer. Aglatimagene is an... Can AI Provide an ‘Early Alert’ for Breast Cancer Before Diagnosis? Three commercially available radiology artificial intelligence (AI) systems have shown the potential to flag early signs of breast cancer up to 6 years before a diagnosis, according to a Swedish study published by Hickman et al in Radiology. Thursday, June 11, 2026 10:49 AM Urologic Surgeon Sworn in as AMA President Willie Underwood III, MD, MSc, MPH, a urologic surgeon based in Buffalo, New York, was sworn on June 9 as the 181st President of the American Medical Association (AMA). Thursday, June 11, 2026 11:00 AM Head and Neck Cancer: HPV-DeepSeek May Identify Earlier Signs of Postoperative Recurrence Researchers clinically validated a sensitive blood test as a whole-genome sequencing assay for detecting circulating tumor human papillomavirus (HPV) DNA in patients with HPV-associated head and neck cancer after surgery to search for residual disease as a sign of potential recurrence, according to ... Thursday, June 11, 2026 12:15 PM FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive Muscle-Invasive Bladder Cancer On May 15, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhbitor atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant therapies for adults with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA... Friday, May 15, 2026 2:22 PM Perioperative Serplulimab in PD-L1–Positive Gastric Cancer In a Chinese phase III study (ASTRUM-006) reported in The Lancet, Shen et al found that neoadjuvant serplulimab plus S-1/oxaliplatin (SOX) followed by adjuvant serplulimab improved event-free survival vs neoadjuvant and adjuvant SOX in patients with PD-L1–positive, resectable gastric or... New Research Links Low Alcohol Consumption to Elevated Health Risks Researchers reported there was no protective net effect of any level of alcohol consumption on health observed in a new study published by George et al in the Journal of Studies on Alcohol and Drugs. Further, researchers reported that low levels of alcohol use may be associated with elevated health ... Tuesday, June 9, 2026 10:15 AM Digital Tool May Improve Patient Engagement in Oncology Clinical Trials In a step forward for patient-centered cancer research, a new pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal (PEP). Alliance created PEP to... Tuesday, June 9, 2026 10:30 AM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
Cancer burden and control in China: landscape, trends and challenges
Over the past decades, cancer epidemiology trends have substantially shifted in China, with a rapid increase in incidence of cancers that are most common in high-income countries and a substantial decline in incidence of cancers historically prevalent in China. The authors of this Review provide an overview of cancer epidemiology in China, a major contributor to global cancer burden, and discuss national cancer control policies and targets. Fri, 19 Jun 2026 00:00:00 -0700 New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer The therapeutic landscape of platinum-resistant ovarian cancer is rapidly evolving, with recent phase III trials demonstrating, for the first time, meaningful overall survival improvements beyond bevacizumab-based therapy. Herein we discuss how trials such as MIRASOL and, more recently, ENGOT-ov65/KEYNOTE-B96 and GOG30173/ENGOT-ov72/ROSELLA have established new standards of care through distinct biologically driven therapies and outline the new challenges that these approaches expose. Wed, 17 Jun 2026 00:00:00 -0700 Antibody–drug conjugates in gynaecological cancers: opportunities and challenges Three antibody–drug conjugates (ADCs) are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 and tisotumab vedotin for cervical cancer (independent of tissue factor expression). The authors of this Review discuss current priorities in the clinical development of ADCs for gynaecological cancers, such as identifying novel targets, understanding mechanisms of resistance and sequencing strategies, and managing toxicities, highlighting key advances and future opportunities. Wed, 17 Jun 2026 00:00:00 -0700 Teclistamab monotherapy improves survival in RRMM Teclistamab monotherapy improves survival in RRMM Mon, 15 Jun 2026 00:00:00 -0700 Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia Fri, 12 Jun 2026 00:00:00 -0700 Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma Fri, 12 Jun 2026 00:00:00 -0700 Adjuvant selpercatinib shows benefit in patients with NSCLC Adjuvant selpercatinib shows benefit in patients with NSCLC Thu, 11 Jun 2026 00:00:00 -0700 Ivonescimab improves overall survival Ivonescimab improves overall survival Thu, 11 Jun 2026 00:00:00 -0700 |
|
|
| |||
|
Predictive model based on folate receptor-positive circulating tumor cells in neoadjuvant immunochemotherapy for esophageal cancer
Vol 17, No 2 (April 30, 2026): Neoadjuvant adebrelimab combined with triplet chemotherapy for locally advanced resectable adenocarcinoma of esophagogastric junction: a prospective, single-arm, phase II feasibility and safety study Vol 17, No 2 (April 30, 2026): The prevalence of gastric intestinal metaplasia in the Saudi population: a single-tertiary center retrospective study Vol 17, No 2 (April 30, 2026): Prognostic impact of low absolute skeletal muscle mass 6 months after gastrectomy for gastric cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Diagnostic value of mini-probe endoscopic ultrasound in preoperative tumor nodal (TN) staging of gastric cancer and analysis of factors influencing T-staging accuracy Vol 17, No 2 (April 30, 2026): Transcatheter arterial embolization with N-butyl cyanoacrylate versus gelatin sponge particles for gastric cancer-related upper gastrointestinal bleeding: a comparison of efficacy and safety Vol 17, No 2 (April 30, 2026): Postoperative frailty among elderly patients undergoing radical surgery for gastrointestinal tumors and its relationship with prognosis Vol 17, No 2 (April 30, 2026): Molecular characteristics and metastatic mechanism of patients diagnosed with Krukenberg tumor from gastric cancer Vol 17, No 2 (April 30, 2026): Retrospective study on clinical outcomes and safety evaluation of da Vinci robot-assisted laparoscopy and endoscopic cooperative for small gastric stromal tumors resection: preliminary single-center experience Vol 17, No 2 (April 30, 2026): The impact of ulinastatin on postoperative clinical outcomes in patients with gastric cancer: a retrospective cohort analysis Vol 17, No 2 (April 30, 2026): Comparison of the efficacy and safety of single-incision versus multi-port laparoscopic D2 lymphadenectomy for locally advanced gastric cancer: a systematic review and meta-analysis Vol 17, No 2 (April 30, 2026): Development and external validation of a prognostic nomogram for cancer-specific survival in elderly patients with early-stage gastric cancer Vol 17, No 2 (April 30, 2026): Identification of immunogenic cell death-related prognostic genes in gastric cancer Vol 17, No 2 (April 30, 2026): Opportunistic CT screening for osteosarcopenia predicts reduced overall survival in patients with gastric cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Patterns of recurrence and outcomes of poor responders to neoadjuvant long-course chemoradiotherapy for rectal cancer Vol 17, No 2 (April 30, 2026): Identification of an autophagy-related prognostic signature and validation of WDR45 in colorectal cancer Vol 17, No 2 (April 30, 2026): KRAS mutation subtypes refine prognostic stratification in colorectal cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Development and validation of manganese metabolism-related genes prognostic model in colorectal cancer and its immunological characteristics Vol 17, No 2 (April 30, 2026): Intratumoral PKM2 expression predicts benefit from adjuvant FOLFOX in stage II–III colorectal cancer Vol 17, No 2 (April 30, 2026): Assessment of colorectal cancer recurrence risk following solid organ transplantation Vol 17, No 2 (April 30, 2026): CCL5 promotes colon cancer progression via PI3K/AKT signaling and is negatively regulated by STAT1 Vol 17, No 2 (April 30, 2026): Molecular subtyping and prognostic model construction based on endosome-related genes in colorectal cancer Vol 17, No 2 (April 30, 2026): No survival benefit from adjuvant chemotherapy in high-risk stage II small intestinal adenocarcinoma after surgery: a population-based long-term survival analysis Vol 17, No 2 (April 30, 2026): Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience Vol 17, No 2 (April 30, 2026): Single-cell transcriptome analysis identifies neutrophil-related prognostic signatures in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): TRNP1 regulates tumorigenesis and enhances immunotherapy response via c-Kit/STAT3 signaling in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Perioperative clinicopathologic model for predicting 12-month early recurrence after curative hepatectomy in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Association of serum lactate dehydrogenase levels with the severity of microvascular invasion in hepatocellular carcinoma: a retrospective cross-sectional study Vol 17, No 2 (April 30, 2026): An exploratory nomogram model with 18F-FDG PET/CT metabolic parameters for predicting high-risk status of microvascular invasion in hepatocellular carcinoma patients prior to liver transplantation Vol 17, No 2 (April 30, 2026): Impact of tumor mutation burden on the prognosis of patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs Vol 17, No 2 (April 30, 2026): Prognostic genes in hepatocellular carcinoma and their function: an analysis integrating high-throughput-based spatial transcriptomics and single-cell RNA-sequencing Vol 17, No 2 (April 30, 2026): PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Development and validation of a model for predicting short-term complications after hepatectomy in patients with primary liver cancer Vol 17, No 2 (April 30, 2026): Temporal change in liver function after stereotactic body radiation therapy for hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): A novel deep learning and radiomics approach based on DCE-MRI for predicting the P53 mutation status in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Peripheral regulatory T cells trajectory predicts progression-free survival in hepatocellular carcinoma patients during on-demand transarterial chemoembolization using joint model: a prospective study Vol 17, No 2 (April 30, 2026): PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study Vol 17, No 2 (April 30, 2026): Indeterminate nodule-like arterial phase hyperenhancement in the liver on CT: differentiation of hepatocellular carcinomas from vascular pseudolesions using a CT radiomics approach Vol 17, No 2 (April 30, 2026): Association between primary tumor resection and survival in metastatic intrahepatic cholangiocarcinoma: a retrospective cohort study based on the SEER database Vol 17, No 2 (April 30, 2026): Multi-scale deep learning models based on MRI for predicting pathological differentiation and evaluating its association with recurrence-free survival in hepatocellular carcinoma: an explainable machine learning study Vol 17, No 2 (April 30, 2026): Daily increment of residual liver regeneration (DIRER) predicts tumor recurrence and mortality after radical hepatectomy for hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Silencing OTUB1 induces pyroptosis to inhibit the growth of liver cancer HepG2 cells via the NLRP3/caspase/GSDM signaling pathway Vol 17, No 2 (April 30, 2026): Targeting AKR1C1 overcomes lenvatinib resistance in hepatocellular carcinoma through the STAT3-ABC transporters pathway Vol 17, No 2 (April 30, 2026): Multi-institutional care is associated with improved survival in biliary tract cancer Vol 17, No 2 (April 30, 2026): Development and validation of machine learning models integrating spectral computed tomography-derived three-dimensional quantitative parameters for predicting histopathological grade in pancreatic ductal adenocarcinoma Vol 17, No 2 (April 30, 2026): A biomarker-integrated nomogram for predicting postoperative pancreatic fistula in low- to intermediate-risk patients after pancreaticoduodenectomy Vol 17, No 2 (April 30, 2026): Impact of preoperative body weight on short-term and long-term prognosis after pancreatic resection for pancreatic ductal adenocarcinoma: a multicenter study Vol 17, No 2 (April 30, 2026): A TRPM4-associated necrotic cell death signature for prognostic stratification in pancreatic cancer Vol 17, No 2 (April 30, 2026): Single-nucleus RNA sequencing reveals the effects of key regulators on human pancreatic adenocarcinoma and its tumor microenvironment Vol 17, No 2 (April 30, 2026): Neoadjuvant radiotherapy after chemotherapy does not improve surgical or survival outcomes in borderline resectable pancreatic cancer Vol 17, No 2 (April 30, 2026): A systematic review of artificial intelligence and machine learning for gut microbiome-based CRC screening Vol 17, No 2 (April 30, 2026): Multimodal data-driven prediction of postoperative recurrence and survival in hepatocellular carcinoma: a narrative review Vol 17, No 2 (April 30, 2026): Risk factors for exclusive lung metastasis in colorectal cancer: a comprehensive narrative review Vol 17, No 2 (April 30, 2026): Advances in mitophagy research in hepatocellular carcinoma: mechanisms and therapeutic implications Vol 17, No 2 (April 30, 2026): A case report of rectal squamous cell carcinoma following radiation therapy for prostate cancer: a management dilemma Vol 17, No 2 (April 30, 2026): Diagnostic challenges in gastrointestinal stromal tumors: a case report of concurrent gastrointestinal stromal tumor, lymphangioma, and solid pseudopapillary neoplasm of the pancreas Vol 17, No 2 (April 30, 2026): Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report Vol 17, No 2 (April 30, 2026): Gastric lymphoma presenting with predominant pancreatitis and cranial neuropathy: a rare clinical presentation—a case report Vol 17, No 2 (April 30, 2026): A case report of gastroesophageal adenocarcinoma with yolk sac tumor differentiation in a pregnant patient Vol 17, No 2 (April 30, 2026): The underestimated global burden and projections of early-onset stomach and early-onset esophageal cancers Vol 17, No 2 (April 30, 2026): Impact of maintenance therapy with fluoropyrimidines in advanced esophageal-gastric adenocarcinoma: a critical review Vol 17, No 2 (April 30, 2026): Methodological clarifications on maintenance fluoropyrimidines in advanced esophagogastric adenocarcinoma: a real-world Mexican cohort Vol 17, No 2 (April 30, 2026): Fruquintinib in refractory metastatic colorectal cancer: separating randomized trial evidence from observational data Vol 17, No 2 (April 30, 2026): Interpreting the evidence base for fruquintinib in refractory metastatic colorectal cancer Vol 17, No 2 (April 30, 2026): Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151 Vol 17, No 2 (April 30, 2026): Personalised neoadjuvant therapy, based on tumour characteristics and patient choice, is the best way forward in rectal cancer Vol 17, No 2 (April 30, 2026): Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? —a decade of debate! Vol 17, No 2 (April 30, 2026): Emerging mechanisms of kinase inhibitor escape and clinical implications of ponatinib in advanced gastrointestinal stromal tumor Vol 17, No 2 (April 30, 2026): When precision medicine meets human behavior: limits of artificial intelligence in predicting imatinib adherence Vol 17, No 2 (April 30, 2026): Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Muscling in on body surface area to reduce oxaliplatin-induced peripheral neuropathy in colon cancer Vol 17, No 2 (April 30, 2026): Clearing the bar: adding anti-VEGF therapy to chemoimmunotherapy for biliary tract cancer Vol 17, No 2 (April 30, 2026): Maximizing the “toolbox” for patients with initially unresectable colorectal liver metastases: have liver mets “met” their match? Vol 17, No 2 (April 30, 2026): The 12-node rule in irradiated rectal cancer: time for reappraisal? Vol 17, No 2 (April 30, 2026): Beyond drug toxicity: the hidden burden of financial toxicity in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Gastrointestinal malignancies in pregnancy: practical considerations Vol 17, No 2 (April 30, 2026): Intrahepatic cholangiocarcinoma: the equity gap in one of the most lethal cancers Vol 17, No 2 (April 30, 2026): Adjuvant chemotherapy in elderly colon cancer patients: when less may be more Vol 17, No 2 (April 30, 2026): Sarcopenia in esophageal cancer: from passive prognostic marker to active treatment target Vol 17, No 2 (April 30, 2026): Return on investment, return of risk: private equity in gastrointestinal cancer care Vol 17, No 2 (April 30, 2026): Tumor necrosis as a key refinement of risk stratification in gastric gastrointestinal stromal tumors Vol 17, No 2 (April 30, 2026): Survival outcomes in early gastric cancer: evidence from SEER-based population studies Vol 17, No 2 (April 30, 2026): Spontaneous rupture of hepatocellular carcinoma: mechanobiology, rescue, and oncologic control Vol 17, No 2 (April 30, 2026): From waste to wealth: malignant ascites-derived organoids as a compass for precision therapy in advanced gastrointestinal cancers Vol 17, No 2 (April 30, 2026): Erratum: Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings Vol 17, No 2 (April 30, 2026): Retraction: Interfering HMGB3 release from cancer-associated fibroblasts by miR-200b represses chemoresistance and epithelial-mesenchymal transition of gastric cancer cells Vol 17, No 2 (April 30, 2026): |
Single-Port Robotic Cytoreductive Surgery for Colon Cancer Peritoneal Recurrence with the da Vinci SP
Fri, 19 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Long-Term Outcomes of Patients with Gastric Cancer and Positive Peritoneal Cytology Fri, 19 Jun 2026 00:00:00 -0700 Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma Fri, 19 Jun 2026 00:00:00 -0700 Distal Resection Margin Collagen Score to Predict Major Low Anterior Resection Syndrome After Neoadjuvant Chemoradiotherapy in Rectal Cancer Fri, 19 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Long-Term Outcomes After Resection of Solitary Colorectal Liver Metastases Thu, 18 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Predicting Failure of Active Surveillance in Desmoid-Type Fibromatosis using Radiomics: An International Multi-center Cohort Study Thu, 18 Jun 2026 00:00:00 -0700 ASO Author Reflections: Robotic Proximal Gastrectomy with Double-Tract Reconstruction and En-Bloc Distal Pancreatectomy: Balancing Oncologic Efficacy and Functional Preservation in Locally Advanced Gastroesophageal Junction Tumors Thu, 18 Jun 2026 00:00:00 -0700 Impact of Surgical Delay on Breast Cancer Prognosis: Systematic Review and Meta-analysis Thu, 18 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Perioperative Risk Stratification in Surgically Treated Endometrial Cancer: The Impact of Nutritional Status and Comorbidity Burden on Morbidity and Survival Wed, 17 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with Longer Survival in Selected Cases: A Systematic Review and Meta-Analysis Wed, 17 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Impact of Muscle Mass Loss on Survival During Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center Retrospective Study in China (TIMES Study) Wed, 17 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Clinical Outcomes of First-Line Immune Checkpoint Inhibitor-Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer Wed, 17 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Development of a Prediction Model for Skin Graft Failure Following Skin Cancer Excision: The GRAFT Score Wed, 17 Jun 2026 00:00:00 -0700 ASO Author Reflections: Serum IgA as a Predictive Biomarker for Immunotherapy in Esophageal Squamous Cell Carcinoma Wed, 17 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma—Results from the Prospective NeoACTIVATE Arm C (NCT03554083) Substudy Wed, 17 Jun 2026 00:00:00 -0700 ASO Author Reflections: Redefining Breast-Conserving Therapy: National Trends in Oncoplastic Reconstruction Wed, 17 Jun 2026 00:00:00 -0700 Two-Year Outcomes after Direct-to-Surgery in Good Prognosis Margin-Clear Stage II or III Rectal Cancer: The QuickSilver Study Wed, 17 Jun 2026 00:00:00 -0700 Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-small-cell Lung Cancer Wed, 17 Jun 2026 00:00:00 -0700 ASO Author Reflections: Local Therapy for Single-Site Recurrent Pancreatic Cancer: Anatomy, Biology, and Selection Tue, 16 Jun 2026 00:00:00 -0700 ASO Author Reflections: The Need for Improved Documentation at Multidisciplinary Tumor Boards Tue, 16 Jun 2026 00:00:00 -0700 Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with Longer Survival in Selected Cases: A Systematic Review and Meta-analysis Tue, 16 Jun 2026 00:00:00 -0700 Combined Impact of Sarcopenia and Low Visceral Adiposity on Postoperative Outcomes and Survival After Esophagectomy for Esophageal Cancer Tue, 16 Jun 2026 00:00:00 -0700 ASO Visual Abstract: High Serum IgA Identifies Poor Responders to Immune Checkpoint Inhibitors in Patients with Unresectable Esophageal Squamous Cell Carcinoma Mon, 15 Jun 2026 00:00:00 -0700 ASO Author Reflections: Trials and Tribulations of Managing Recurrent Uterine Leiomyosarcoma Mon, 15 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Complete Segmental Parenchymal Vascular Occlusion for Robotic Enucleation of Distal Pancreatic Tumors (with video) Mon, 15 Jun 2026 00:00:00 -0700 ASO Author Reflections: Prognostic Biomarkers for Surgical Selection in Pulmonary Metastases from Hepatocellular Carcinoma Mon, 15 Jun 2026 00:00:00 -0700 ASO Author Reflections: Surgical Management of Urachal Cancer in Germany: A Nationwide Analysis from 2006 to 2022 Mon, 15 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Benefit of Adjuvant Therapy after Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis Mon, 15 Jun 2026 00:00:00 -0700 ASO Author Reflections: From Intuition to Quantification: Elevating Gastric Tube Perfusion Assessment in Esophageal Cancer Surgery Mon, 15 Jun 2026 00:00:00 -0700 Risk of pN2/3 Understaging in Sentinel Node-Positive ER+/HER2− Breast Cancer: A Composite Clinicopathologic Score for Safe RxPONDER and MonarchE Application Mon, 15 Jun 2026 00:00:00 -0700 Robotic Anatomic Segmentectomy 8 of the Liver Using a Hepatic Vein-Guided Approach and Indocyanine Green Fluorescence Imaging (With Video) Mon, 15 Jun 2026 00:00:00 -0700 The Surgical Outcomes of Brachiocephalic Vein Transection Versus Reconstruction for Locally Advanced Thymic Epithelial Tumors Mon, 15 Jun 2026 00:00:00 -0700 ASO Visual Abstract: The Impact of a Regional Communities of Practice to Improve Quality of Melanoma Care: Setting Guidelines for Preoperative Diagnostic Imaging in Early-Stage Melanoma Sun, 14 Jun 2026 00:00:00 -0700 ASO Author Reflections: T12-Sarcopenia After Neoadjuvant Chemoimmunotherapy Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma Sun, 14 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Predictive Features Specific to FIGO IIIA1 Ovarian Cancer: What Drives Prognosis Sun, 14 Jun 2026 00:00:00 -0700 Robotic Multivisceral Resection for Gastroesophageal Junction Tumor: Proximal Gastrectomy with Double-Tract Reconstruction and Distal Pancreatectomy Sun, 14 Jun 2026 00:00:00 -0700 ASO Author Reflections: A Novel Technique of Externalized Pancreatic Stenting in Robotic Pancreaticoduodenectomy—Initial Experience and Outcomes Sun, 14 Jun 2026 00:00:00 -0700 ASO Visual Abstract: Survival Outcomes in Early-Onset Appendiceal Adenocarcinoma (EOAA) Sun, 14 Jun 2026 00:00:00 -0700 ASO Author Reflections: The Role of Neoadjuvant Chemotherapy in the Management of Primary Retroperitoneal Germ Cell Tumors in Children Sun, 14 Jun 2026 00:00:00 -0700 Pathologic Upstaging in Local Recurrence After Partial Nephrectomy: Distinct Biologic Behavior and Clinical Prognosis of Original-Site Versus Non–Original-Site Recurrence Sun, 14 Jun 2026 00:00:00 -0700 Comparing Resident Team Performance in Complex Surgical Oncology: A Single-Institution Cohort Study Sun, 14 Jun 2026 00:00:00 -0700 Longitudinal Symptom Recovery After Pancreatectomy: A Prospective Patient-Reported Outcomes Study using MDASI Sun, 14 Jun 2026 00:00:00 -0700 Predominance of Peritoneal Metastasis in the Recurrence Pattern of T4 Colorectal Cancer: A Retrospective Cohort Study Sun, 14 Jun 2026 00:00:00 -0700 Benchmarking Large Language Models for Bladder Cancer: Comparative Knowledge Retrieval and Clinical Reasoning of DeepSeek and ChatGPT Sun, 14 Jun 2026 00:00:00 -0700 Survival Comparison of Proximal and Total Gastrectomy after Neoadjuvant Therapy in Siewert Type II/III Gastric Adenocarcinoma: A Real-World Multicenter Cohort Study Sun, 14 Jun 2026 00:00:00 -0700 Tumor Burden Modifies the Prognostic Impact of Adequate Lymph Node Dissection in Patients Undergoing Curative-Intent Resection for Intrahepatic Cholangiocarcinoma Sun, 14 Jun 2026 00:00:00 -0700 Correction: ASO Visual Abstract: Well‑Differentiated Liposarcoma of the Psoas Muscle: A Distinct Anatomic Subset with Highly Favorable Outcomes Fri, 12 Jun 2026 00:00:00 -0700 ASO Visual Abstract: From Clinical Trial Awareness to Practice—Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Clinical Trial Fri, 12 Jun 2026 00:00:00 -0700 High-Intensity Focused Ultrasound Versus Robot-Assisted Radical Prostatectomy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Oncologic and Functional Outcomes Fri, 12 Jun 2026 00:00:00 -0700 ASO Video Abstract: A Stepwise Approach to Laparoscopic Mesohepatectomy: From Complexity to Standardization with Video Demonstration Thu, 11 Jun 2026 00:00:00 -0700 |
||
|
| |||
|
Rapid Evaluation of Artificial Intelligence Technology Used for Ambient Dictation in Primary Care: Comparing the Quality of Documentation of Artificial Intelligence–Generated and Human-Produced Clinical Notes
Annals of Internal Medicine, Volume 179, Issue 6, Page 765-772, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Effectiveness of Nonpharmacologic Treatments for Chronic Low Back Pain Annals of Internal Medicine, Volume 179, Issue 6, Page 773-784, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Low-Volume Polyethylene Glycol for Bowel Preparation in Hospitalized Adults Annals of Internal Medicine, Volume 179, Issue 6, Page 785-793, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Initiation of Medications for Alcohol Use Disorder Among Hospitalized Veterans Annals of Internal Medicine, Volume 179, Issue 6, Page 794-803, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Twenty-Three–Year Benefits of Sigmoidoscopy Screening for Colorectal Cancer Annals of Internal Medicine, Volume 179, Issue 6, Page 804-811, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Proximal Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in the OSPREY Study Annals of Internal Medicine, Volume 179, Issue 6, Page 812-822, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine Annals of Internal Medicine, Volume 179, Issue 6, Page 823-834, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2) Annals of Internal Medicine, Volume 179, Issue 6, Page 842-856, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 How Would You Manage This Patient With Iron Deficiency Anemia? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 179, Issue 6, Page 857-867, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Core Performance Measures for Migraine Headache: A Review by the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 6, Page 835-838, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Reforming 340B to Promote Program Integrity and Better Serve Vulnerable Populations: An American College of Physicians Policy Brief Annals of Internal Medicine, Volume 179, Issue 6, Page 839-841, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 “Never More Than 15 Feet From the Respirator”: Housestaff Research During the 1955 Boston Polio Epidemic Annals of Internal Medicine, Volume 179, Issue 6, Page 868-873, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Integrating Planetary Health in Health Guidelines (GRADE Guidance 46) Annals of Internal Medicine, Volume 179, Issue 6, Page 874-884, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 The Importance of the Childhood Immunization Schedule for Internal Medicine Annals of Internal Medicine, Volume 179, Issue 6, Page 885-888, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Reframing Social Drivers of Health in Patient Quality and Safety Annals of Internal Medicine, Volume 179, Issue 6, Page 889-891, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Automatic Tenure-Clock Extensions as a Safeguard Against Defunding Annals of Internal Medicine, Volume 179, Issue 6, Page 892-894, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 What FDA Clearance Does, and Does Not, Mean for Artificial Intelligence Annals of Internal Medicine, Volume 179, Issue 6, Page 895-897, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Redefining Documentation Quality in the Age of Ambient Artificial Intelligence Scribes Annals of Internal Medicine, Volume 179, Issue 6, Page 898-899, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Incorporating Planetary Health Into Clinical Guideline Decisions Annals of Internal Medicine, Volume 179, Issue 6, Page 900-901, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 A Kite Without a String Annals of Internal Medicine, Volume 179, Issue 6, Page 902, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Cleo Annals of Internal Medicine, Volume 179, Issue 6, Page 903-904, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 All the Way Down Annals of Internal Medicine, Volume 179, Issue 6, Page 905-906, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Risk-Guided Antihypertensive Treatment Eligibility in Older Adults Under Updated Hypertension Guidelines Annals of Internal Medicine, Volume 179, Issue 6, Page 908-911, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Amputation Rates Among Opioid-Related Hospitalizations in the United States, 2016 to 2022 Annals of Internal Medicine, Volume 179, Issue 6, Page 911-914, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 The Effect of 4:3 Intermittent Fasting on Weight Loss at 12 Months Annals of Internal Medicine, Volume 179, Issue 6, Page 915-916, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Dollars Needed to Pay per Early-Detected Colorectal Cancer Case in Stool-Based Screening Annals of Internal Medicine, Volume 179, Issue 6, Page 914, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
New biotech cAMPfield emerges with $180M to reshape IBD treatment
Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.
Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.
Mirum, Incyte bolster case for approval in rare bone disease despite mid-stage miss While falling short of statistical significance, Incyte and Mirum Pharmaceuticals’ ALK2 inhibitor showed a “clear benefit” in reducing abnormal bone formation in a Phase 2 study of fibrodysplasia ossificans progressiva.
Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3 Elicio Therapeutics’ investigational cancer immunotherapy failed to meet the primary endpoint of disease-free survival in a Phase 2 trial—a result the company attributed mostly to a disproportionate number of patients with higher residual disease.
Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in a mid-stage trial of advanced melanoma—a result analysts said could help “instill confidence” in the regimen.
ASCO: Biopharma has pancreatic cancer ‘surrounded’ as Immuneering’s drug adds 9 quality months In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated a robust tolerability profile—something CEO Ben Zeskind said equates highly with survival.
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing both primary and secondary endpoints.
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 Congress Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) Memo Therapeutics AG Presents Complete Phase II Clinical Trial Data for Potravitug in Kidney Transplant Recipients at the American Transplant Congress 2026 AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer’s Patients Neuron23 to Accelerate Expansion of NEULARK Phase 2 Trial with Support from The Michael J. Fox Foundation Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis Step Pharma advances dencatistat into phase 2 clinical trial for essential thrombocythaemia |
Intellia’s gene editor ‘keeps pace’ with Ionis in hereditary angioedema
With a one-time dosing profile, Intellia Therapeutics’ gene editing asset could be “paradigm-shifting” for hereditary angioedema, according to Jefferies. The biotech anticipates market approval next year.
Neumora discards depression asset, lays off staffers after pair of late-stage flops Neumora Therapeutics is laying off 35% of workers after its most advanced asset failed a pair of Phase 3 studies, sending the biotech’s stock spiraling early Monday.
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.
Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug class, according to William Blair.
ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
ADA: Metsera asset data support Pfizer’s ‘entry point’ into obesity market Much work needs to be done for Pfizer to be able to catch up to the weight-loss frontrunners, according to Guggenheim Partners, but new data from Metsera’s lead asset could set the pharma apart from competitors with a monthly injection.
ADA: Lilly sets ‘new record in Weight Loss Olympics’ with next-gen asset Over two years of treatment, Eli Lilly’s triple-G drug cut body weight by more than 30% in certain patients with obesity, cementing the pharma’s position as the frontrunner in the metabolic space.
Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data By inhibiting the APRIL cascade, Otsuka Pharmaceuticals’ Voyxact slowed kidney function decline in patients with IgAN, opening up a potential path for full approval while also reading through to Vertex and others with similar assets.
ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.
Celcuity slides even after ‘practice-changing’ late-stage breast cancer data Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer IntraBio Announces Publication of Pivotal Phase III Data with Levacetylleucine for Ataxia-Telangiectasia in The Lancet Neurology FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive Aspergillosis Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia Vera J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) Humacyte’s Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 Atom Therapeutics to Update Clinical Trials of Its Lead Drugs, a URAT1 Inhibitor for Chronic Gout and New Anti-Inflammatory Drug for Acute Gout Flares, at the BIO International Convention 2026 in San Diego Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL |
New biotech cAMPfield emerges with $180M to reshape IBD treatment
Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.
From fragile skin to living medicine: Lessons from RDEB In this episode of Denatured, you’ll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We explore how recessive dystrophic epidermolysis bullosa has become a defining case study for gene and cell therapy and what this ultra‑rare disease reveals about the future scalability of advanced therapies.
Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.
Convert nonresponder insights into smarter drug development strategies in immunology While agents like AbbVie’s Humira have transformed the treatment landscape, not all patients benefit equally from the drug. Better biomarker analysis and more investment in mechanistic trials can inform the development of more effective therapies with broader clinical value.
Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short Although Edgewise Therapeutics’ hypertrophic cardiomyopathy asset missed expectations, Truist Securities called the data “excellent,” leaning on a safety profile that could eliminate the need for risk evaluation and mitigation strategies.
Mirum, Incyte bolster case for approval in rare bone disease despite mid-stage miss While falling short of statistical significance, Incyte and Mirum Pharmaceuticals’ ALK2 inhibitor showed a “clear benefit” in reducing abnormal bone formation in a Phase 2 study of fibrodysplasia ossificans progressiva.
Intellia’s gene editor ‘keeps pace’ with Ionis in hereditary angioedema With a one-time dosing profile, Intellia Therapeutics’ gene editing asset could be “paradigm-shifting” for hereditary angioedema, according to Jefferies. The biotech anticipates market approval next year.
Neumora discards depression asset, lays off staffers after pair of late-stage flops Neumora Therapeutics is laying off 35% of workers after its most advanced asset failed a pair of Phase 3 studies, sending the biotech’s stock spiraling early Monday.
Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3 Elicio Therapeutics’ investigational cancer immunotherapy failed to meet the primary endpoint of disease-free survival in a Phase 2 trial—a result the company attributed mostly to a disproportionate number of patients with higher residual disease.
Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases Astrogen Inc. Receives 18th Folia Award for Outstanding Clinical Research in Autism Spectrum Disorder Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University International Myeloma Foundation’s Black Swan Research Initiative Presents Data and Results of Phase 2 ASCENT Cure Trial at EHA 2026 Congress Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model Paradigm Clinical Research Opens Psychedelic Research Suite in Redding, California Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) Memo Therapeutics AG Presents Complete Phase II Clinical Trial Data for Potravitug in Kidney Transplant Recipients at the American Transplant Congress 2026 IntraBio Announces Publication of Pivotal Phase III Data with Levacetylleucine for Ataxia-Telangiectasia in The Lancet Neurology AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive Aspergillosis Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 |
|
|
| |||
|
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
Thu, 28 May 2026 00:00:02 -0700
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wed, 27 May 2026 00:00:02 -0700
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Fri, 22 May 2026 00:00:02 -0700
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
Fri, 15 May 2026 00:00:02 -0700
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
Fri, 15 May 2026 00:00:02 -0700
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Wed, 13 May 2026 00:00:02 -0700
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Wed, 13 May 2026 00:00:02 -0700
FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
Fri, 08 May 2026 00:00:02 -0700
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Fri, 01 May 2026 00:00:02 -0700
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Wed, 25 Mar 2026 00:00:02 -0700
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
Fri, 20 Mar 2026 00:00:02 -0700
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 05 Mar 2026 00:00:02 -0800
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Thu, 26 Feb 2026 00:00:02 -0800
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
Tue, 24 Feb 2026 00:00:02 -0800
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Thu, 19 Feb 2026 00:00:02 -0800
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Tue, 10 Feb 2026 00:00:02 -0800
Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency Thu, 05 Feb 2026 00:00:02 -0800
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Tue, 27 Jan 2026 00:00:02 -0800
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
Wed, 17 Dec 2025 00:00:02 -0800
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).
Wed, 17 Dec 2025 00:00:02 -0800
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
Mon, 15 Dec 2025 00:00:02 -0800
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
Fri, 12 Dec 2025 00:00:02 -0800
|
More warnings about over-the-counter supplements containing hidden drugs.
Am J Nurs. 2026 Jun 1;126(6):23. doi: 10.1097/AJN.0000000000000313a. Epub 2026 May 21. Aschenbrenner DS Liver injury from herbal and dietary supplements. Hepatology. 2017 Jan;65(1):363-373. doi: 10.1002/hep.28813. Epub 2016 Nov 17. Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH Life-span-dependent transcriptional dynamics of the human heart. Sci Adv. 2026 Jun 19;12(25):eaeg2614. doi: 10.1126/sciadv.aeg2614. Epub 2026 Jun 17. Jia H, Chen X, Chang Y, Wang Y, Lindberg EL, Cui H, Feng Y, Zhang N, Zhang X, Xu M, Shan D, Sheng Y, Wei F, Hua X, Mo H, Hu Y, Shao X, Han H, Reichart D, Song J Cellular architecture and neighborhood-informed virtual spatial tumor profiling from histopathology. Cell. 2026 Jun 16:S0092-8674(26)00590-8. doi: 10.1016/j.cell.2026.05.031. Li Y, Li Z, Quinton R, Ji Y, Zhang X, Xiang J, Wang X, Yang S, Eweje F, Chen Y, Luo X, Li Y, Mulholland J, Chen S, Bergstrom C, Kim T, Maria Olguin F, Willens S, Lin SH, Nirschl JJ, West R, Neal J, Diehn M, Li R Management of Differentiated Thyroid Cancer. N Engl J Med. 2026 Jun 18;394(23):2340-2355. doi: 10.1056/NEJMra2416814. Hegedüs L, Wirth LJ, Tuttle RM Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial. Lancet. 2026 Jun 17:S0140-6736(26)00761-0. doi: 10.1016/S0140-6736(26)00761-0. Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Cancer Cell. 2026 Jun 18:S1535-6108(26)00265-5. doi: 10.1016/j.ccell.2026.05.020. Liao J, Yao W, Yu Y, Li A, Huang J, Li X, Sun L, Zhang Y, Wang Y, Qu X, Zhao J, Wang H, Zhuang W, Hu L, Chen X, Pang L, Yang M, Chen Z, Zhang Y, Li T, Yu W, Zeng Y, Li J, Kataria R, Blumenthal G, Akala O, Liu Y, Shen Y, Ge J, Hong S, Yang Y, Zhang L, Fang W Maternal trans-vaccenic acid shapes neonatal T cell development and early-life immune imprinting. Science. 2026 Jun 18;392(6804):eaea4041. doi: 10.1126/science.aea4041. Epub 2026 Jun 18. Fan H, Zheng Z, Oliphant K, Li J, Mack R, Ju CW, Trandai B, Tu J, Zhang FQ, Zhang R, Xie Z, Yin C, Cai C, Kennedy MS, McNeely T, Cham C, Shah H, Dong L, Su R, Martin CR, Layden BT, Hamanaka RB, Mutlu GM, Chang EB, Zhang J, Chi H, Claud EC, He C, Chen J Plasma proteomic signatures of cellular aging predict human disease. Nat Med. 2026 Jun;32(6):2060-2072. doi: 10.1038/s41591-026-04446-y. Epub 2026 Jun 15. Ding DY, Bot VA, Chen KL, Groves JW, Pálovics R, Masuda D, Farinas A, Oh HS, Wagner V, Lu N; Global Neurodegeneration Proteomics Consortium (GNPC); Cruchaga C, Isakova A, Schott JM, Wyss-Coray T A CRISPR knockout mouse library for functional genomics in influenza research. Cell. 2026 Jun 16:S0092-8674(26)00591-X. doi: 10.1016/j.cell.2026.05.032. Ueki H, Tomita Y, Duong C, Mitake H, Kiso M, Furusawa Y, Zhao D, da Silva Lopes TJ, Wu L, Feng H, Yamayoshi S, Fukuyama S, Yamashita M, Ozawa M, Ikawa M, Yoshida N, Watanabe T, Kawaoka Y Nuclear export of R-loop by the DDX1 and XPO1 complex promotes senescence-associated secretory phenotype and inflammaging. Nat Aging. 2026 Jun;6(6):1208-1226. doi: 10.1038/s43587-026-01147-6. Epub 2026 Jun 16. Hao X, Zhao B, Yan Q, Yano M, Matsuoka A, Qi Y, Liao L, Zielinski RJ, Tang HY, Kossenkov AV, Zal MA, Sarma K, Zhang R Functional and dysfunctional T regulatory cell states in human tissues in RA and other autoimmune arthritic diseases. Nat Immunol. 2026 Jun 16. doi: 10.1038/s41590-026-02540-4. Koh B, Gal Oz ST, Sato R, Nguyen HN, Dunlap G, Mahony C, Bolton C; Accelerating Medicines Partnership (AMP) RA/SLE Network; Wedderburn LR, Croft AP, Donlin L, Smith MH, Raychaudhuri S, Korsunsky I, Rao DA, Brenner MB Combined acetaldehyde metabolism burden modifies IBD susceptibility to alcohol consumption. Gut. 2026 Jun 17:gutjnl-2026-338262. doi: 10.1136/gutjnl-2026-338262. Chen J, Guo Y, Hu J, Ye S, Yao J, Yanai H, Jairath V, Peyrin-Biroulet L, Dan L, Li X, Wang X, Magro F Laparoscopic management of Mirizzi syndrome type IV: a case report and review of minimal access surgery. J Minim Invasive Surg. 2026 Jun 15;29(2):97-101. doi: 10.7602/jmis.2026.29.2.97. Nguyen NBM, Pham TH, Pham TQ, Nguyen DV, Nguyen PH Low rates of cancer or high-grade dysplasia in colorectal polyps collected from computed tomography colonography screening. Clin Gastroenterol Hepatol. 2010 Jul;8(7):610-5. doi: 10.1016/j.cgh.2010.03.007. Epub 2010 Mar 19. Pickhardt PJ, Hain KS, Kim DH, Hassan C Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data. Lancet. 2026 Jun 17:S0140-6736(26)00918-9. doi: 10.1016/S0140-6736(26)00918-9. Sasieni P, Falcaro M Targeting PID1 generates oxysterols to switch macrophage cell fates for improved antitumor immunity. Nat Cancer. 2026 Jun 16. doi: 10.1038/s43018-026-01189-0. Zheng Y, Wang Q, Dong C, Wang Q, Han M, Zhao H, Wang S, Chen L, Zhang X, Yang D, Xiao J, Chew Z, Xie Z, Yang L, Fan J, Zheng X, Tu D, Li W, Zheng L, Hui L, Huang X, Li J, Tang H, Wei B, Wang H Auxin-mediated cell cycle activation during early lateral root initiation. Plant Cell. 2002 Oct;14(10):2339-51. doi: 10.1105/tpc.004960. Himanen K, Boucheron E, Vanneste S, de Almeida Engler J, Inzé D, Beeckman T Position of pelvis in the 3rd month of life predicts further motor development. Hum Mov Sci. 2018 Jun;59:37-45. doi: 10.1016/j.humov.2018.03.007. Epub 2018 Mar 27. Gajewska E, Sobieska M, Moczko J Feasibility of the TAIPEI procedure for penile straightening in hypospadias: Insights from families. J Pediatr Urol. 2026 Apr 18:105965. doi: 10.1016/j.jpurol.2026.105965. Ting CS, Ting SW, Tseng MH, Tsai LP, Chee SY, Chang PY |
||